ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.
Nabil F Saba et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.